Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Monoamine oxidase B (MAO-B) is a mitochondrial enzyme primarily known for its role in the breakdown of neurotransmitters like dopamine. In the context of neurodegenerative conditions such as Alzheimer's disease, MAO-B becomes significantly upregulated in reactive astrocytes. This 'novel' pathological role involves the aberrant production of GABA and hydrogen peroxide, which leads to tonic inhibition of neighboring neurons and oxidative stress. Modern therapeutic strategies, such as the development of the reversible inhibitor KDS2010, aim to selectively block astrocytic MAO-B to reverse cognitive decline and slow disease progression. Unlike traditional MAO inhibitors used in Parkinson's, these next-generation candidates focus on the specific metabolic shift in glia rather than just neurotransmitter preservation.
Reversible or irreversible inhibition of the MAO-B enzyme to reduce the production of inhibitory GABA and toxic hydrogen peroxide in reactive astrocytes, thereby restoring neuronal signaling and reducing neuroinflammation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Monoamine oxidase B (MAO-B) (MAO-B).